Supplementary Figure S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

<p>Figure S2. Batiraxcept and docetaxel alone or in combination significantly inhibited bone tumor growth and metastasis in LuCaP mPCa AC PDX models. A-B, Representative images of Masson-Goldner staining and Ku70 IHC of PDX cells in the tibiae of LuCaP 147 (A), and LuCaP 35 (B). Human PCa cells marked by Ku70 were significantly decreased after 30 days of treatment by intraperitoneal injection with batiraxcept (20 mg/kg/QOD, n = 8–9, docetaxel (10 mg/kg/QW, n = 9) or the combination of batiraxcept (20 mg/kg/QOD, n = 9) and docetaxel (10 mg/kg/QW, n = 9) compared to vehicle controls (n = 8,10). C-D, Quantification of the IHC Ku70-positive areas in mouse tibia specimens treated with vehicle, batiraxcept, docetaxel, and batiraxcept + docetaxel in A-B. Fold change: combination batiraxcept and docetaxel (B+D) group set as 1. E, Inhibition of LuCaP 147CR tumor cells metastasis to mouse lung lobes by batiraxcept, docetaxel, and batiraxcept + docetaxel combination therapy. The arrowheads indicate Ku70-positive metastatic tumor nodules in the lung, which metastasized from the mice tibiae. F, Quantification of fold changes (docetaxel group set as 1) of human-specific GAPDH level normalized against universal GAPDH level in different treatment groups for LuCaP 147CR. *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, p > 0.05 not significant. All scale bar = 50 μm.</p>

Duke Scholars

Author Spencer Hauck  

Author Jiaoti Huang Pathology